IRVING, Texas, July 31, 2024 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR), the world's leading company turning food waste into sustainable products and producer of renewable energy, today announced that its 50/50 joint venture Diamond Green Diesel (DGD) will provide the first regular supply of neat sustainable aviation fuel (SAF), to be blended with conventional jet fuel to create blended SAF, for commercial air travel out of John F. Kennedy International Airport (JFK) to begin in the next few month ...

ATHENS, Greece, July 31, 2024 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX), (the "Company"), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today reported a net loss of $2.8 million and a net loss attributed to common stockholders of $4.2 million for the second quarter of 2024. This compares to net income of $10.4 million and net income attributed to common stockholders of $8.9 million for the second quarter of 2023. Loss per share for the second ...

文章核心观点 - 美国FDA授予公司的VCN-01用于治疗视网膜母细胞瘤的罕见儿童药物指定[1][2][3] - VCN-01是一种全身性的选择性肿瘤溶解腺病毒,可以多方面抑制肿瘤生长[5] - 公司正在与医生和监管机构密切合作,优化VCN-01在儿童晚期视网膜母细胞瘤中的临床开发策略[2] - 最近一项针对复发性视网膜母细胞瘤的I期临床试验结果显示积极[2] 行业概况 - 视网膜母细胞瘤是儿童最常见的眼部肿瘤,每年在美国约有200-300例新发病例[4] - 保存生命和避免失明等严重后果仍然是一大挑战[4] - 在资源匮乏的国家,儿童视网膜母细胞瘤患者更容易失去眼睛并死于转移性疾病[4] 公司概况 - 公司是一家多元化的临床阶段生物制药公司,专注于开发治疗癌症和相关疾病的新药[6][7] - 公司的主要产品包括VCN-01、SYN-004和SYN-020,涉及多种适应症[6][7] - 如果VCN-01获批上市,公司可能有资格获得优先审评券[3] - 公司目前现金储备可提供到2025年第一季度的运营资金[8]

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment, alone and in combination with lecanemab, protected cultures of primary neurons from the toxic effects of amyloid-β BOTHELL, Wash., July 31, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow n ...

WALTHAM, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of plain language summaries of results from two clinical trials on XPHOZAH® (tenapanor), NORMALIZE and OPTIMIZE, in Current Medical Research and Opinion. The plain language summaries were developed by the authors to help adult pati ...

Delivers 15.0% Unit Growth Domestic Same Store Sales Increased 28.7%, Driven by Transaction Growth DALLAS, July 31, 2024 /PRNewswire/ -- Wingstop Inc. (NASDAQ: WING) today announced financial results for the fiscal second quarter ended June 29, 2024. Highlights for the fiscal second quarter 2024 compared to the fiscal second quarter 2023: System-wide sales increased 45.2% to $1.2 billion 73 net new openings in the fiscal second quarter 2024 Domestic restaurant AUV increased to $2.0 million Domestic same st ...

Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (NASDAQ:PWUP), a Nasdaq Global Market® listed special purpose acquisition company ("PowerUp"), today announced that they have signed a non-binding letter of intent ("LOI") for a potential business combination ("Business Combination"). Under the terms of the LOI, followin ...

DALLAS, July 31, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced continuing progress in the development of DeepView SnapShot® M, a handheld diagnostic tool targeted for use in battlefield burn assessment that is based on the Company's AI-driven DeepView™ System platform. Burn wounds account for a significant portion ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. ("OLAPLEX"), today announced their participation in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA. Amanda Baldwin, Chief Executive Officer will present on Wednesday, August 14, 2024 at 10:00am ET, and will meet with investors during the conference. The audio portion of the presentation will be available on the Company's Investor Relations website, https://ir.olaplex.com/, and will remain there for 90 days following the ev ...

关于Achieve Life Sciences公司 - 公司为致力于全球开发和商业化用于戒烟和尼古丁依赖的cytisinicline的后期制药公司[1] - 美国食品药品监督管理局（FDA）已授予cytisinicline用于尼古丁电子烟（或 vaping）戒烟的突破性疗法认定[1] - 公司总裁兼首席医疗官称美国有超1300万吸电子烟且努力克服成瘾的人目前没有FDA批准的专门用于戒烟的药物cytisinicline有潜力成为一流治疗方法[2] - 突破性疗法认定旨在加快用于治疗严重疾病药物的开发和审查且初步临床证据表明该药物可能比现有疗法有显著改善[2] - 公司计划在今年年底前与FDA多学科团队举行2期结束会议[2] - FDA认为烟草依赖是严重或危及生命的状况长期使用电子烟也被认为是严重状况[3] - 青少年和年轻成人使用电子烟存在风险包括对大脑发育的潜在风险和尼古丁成瘾风险[3] - 公司的2期ORCA - V1试验结果表明接受cytisinicline治疗的参与者戒烟的可能性是接受安慰剂的2.6倍[4] - 在其他次要终点也发现了有利于cytisinicline的趋势且cytisinicline治疗耐受性良好无严重不良事件报告依从性良好[4] - 2期ORCA - V1临床研究部分由美国国立卫生研究院（NIH）国家药物滥用研究所支持[5] - 2期ORCA - V1试验评估了美国5个临床试验点的160名吸电子烟的成年人[6] - 参与者随机接受3mg cytisinicline或安慰剂并结合标准戒烟行为支持为期12周[6] - ORCA - V1研究中cytisinicline的剂量和给药方式与3期注册试验相同[6] - 公司专注于通过cytisinicline的开发和商业化解决全球吸烟健康和尼古丁成瘾流行问题[7] - 美国约有2900万成年人吸食可燃香烟烟草使用是全球可预防死亡的主要原因[7] - 美国有超过1100万成年人使用电子烟2023年美国约有210万中学生和高中生报告使用电子烟[7] - 目前没有FDA批准的专门用于尼古丁电子烟戒烟的治疗方法[8] - cytisinicline是一种植物性生物碱与烟碱型乙酰胆碱受体有高亲和力[8] - 它被认为可通过与大脑中的尼古丁受体相互作用减轻戒断症状降低尼古丁产品的奖励和满意度来帮助治疗尼古丁成瘾[8] - cytisinicline是一种正在开发的用于治疗尼古丁成瘾的候选产品尚未在美国获得FDA批准用于任何适应症[8]